NOTE TO READERS: When this project lost substantial funding at the end of 2018, I lost the ability to continue publishing criteria-driven news story reviews and PR news release reviews - once the bread-and-butter of the site going back to 2006. The 3,200 archived reviews, while still educational, are getting old and difficult for me to technically maintain on the back end of the website. So I am announcing that I plan to remove these reviews from the site by April 1, 2021. The blog and the toolkit - two of the most popular features on the site - will remain. If you wish to peruse the reviews before they disappear, please do so by the end of March 2021. After that date you may still be able to access them via the Internet Archive Wayback Machine - https://archive.org/web/.

Categories: Cardiovascular disease

7 9/26/2018

STAT’s cheerleading coverage of prescription fish oil capsule lacks crucial context

3/14/2017

Reuters Health lays out pros and cons of high resolution screening for heart patients; skimps on study limitations

4/28/2016

Medical Daily story on Mediterranean diet study mostly echoes news release

4/25/2016

NBC story built around one patient’s amazing stroke recovery; skimps on data suggesting result is unusual

5 4/14/2016

Solid effort by NBC on saturated fat study, though story lacked hard numbers on findings

1/7/2016

Newer blood pressure meds “as good as old ones” — but at doing what exactly?

1/7/2016

A gloss over costs in coverage of competing blood pressure meds — but also some strengths

10/15/2015

“Wine can help” those with type 2 diabetes, says LA Times, but benefits aren’t quantified (and are actually quite small)

3 10/8/2015

Optimal balance of competing views on value of CT heart scans

9/26/2015

Texting your way to heart health? NPR thoroughly examines the evidence

Story Reviews

Systematic, Criteria-Driven

@HealthNewsRevu

HealthNewsRevuHealthNewsReview.org@HealthNewsRevu·

.@TranspariMED criticizes STAT op-ed for not disclosing pharma funding of author’s institute - similar to criticism we’ve made of STAT op-eds in the past. @transparify @ThinkTankWatch @icer_review https://www.healthnewsreview.org/2021/02/transparency-watchdog-criticizes-stats-non-disclosure-on-pro-pharma-op-ed/

Reply on Twitter 1360214949704982532Retweet on Twitter 13602149497049825323Like on Twitter 13602149497049825328Twitter 1360214949704982532
Retweet on TwitterHealthNewsReview.org Retweeted
ContentScienceContent Science@ContentScience·

If you’re covering COVID-19, you need a robust understanding of how to report on health and science news (and when you're in over your head). Get a leg up with these insights from @garyschwitzer.

https://review.content-science.com/health-and-science-communication-in-the-covid-era-a-qa-with-the-publisher-of-health-news-review/

Reply on Twitter 1359955873561518085Retweet on Twitter 13599558735615180852Like on Twitter 13599558735615180851Twitter 1359955873561518085
HealthNewsRevuHealthNewsReview.org@HealthNewsRevu·

Tech sites @MacRumors & @TechCrunch hype #AppleWatch’s ability to predict #COVID19 without providing the evidence. @mtmdphd was keen observer. https://www.healthnewsreview.org/2021/02/tech-sites-hype-apple-watch-for-covid-19-prediction-without-providing-the-evidence/

Reply on Twitter 1359860468135964683Retweet on Twitter 13598604681359646832Like on Twitter 13598604681359646834Twitter 1359860468135964683
View More

Categories

View More

Tags